<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868140</url>
  </required_header>
  <id_info>
    <org_study_id>VCUIRB4480</org_study_id>
    <secondary_id>GCRC0824</secondary_id>
    <nct_id>NCT00868140</nct_id>
  </id_info>
  <brief_title>Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)</brief_title>
  <acronym>PCOS</acronym>
  <official_title>Determination if Indirectly Reducing Circulating Insulin by Improving Insulin Sensitivity With Pioglitazone Reduces Renal Clearance of D-chiro-inositol (DCI) Increases the Circulating Concentration of DCI and Enhances Insulin-stimulated Release of the D-chiro-inositol-containing Inositolphosphoglycan (DCI-IPG) Mediator in Obese Women With PCOS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that hyperinsulinemia increases the renal clearance of D-chiro-inositol
      (DCI) in women with polycystic ovary syndrome (PCOS) and that this leads to a reduction in
      circulating insulin-stimulated D-chiro-inositol-containing inositol phosphoglycan (DCI-IPG)
      release. To assess the effects of a chronic reduction in circulating insulin on DCI
      metabolism, we propose to reduce circulating insulin in obese women with PCOS by improving
      insulin sensitivity with the drug pioglitazone. Pioglitazone is a thiazolidinedione that
      improves peripheral insulin sensitivity, presumably by activation of the peroxisome
      proliferator-activated receptor gamma (PPARÎ³) receptor. Administration of pioglitazone to
      women with PCOS has been shown to improve insulin sensitivity, reduce insulin secretion, and
      decrease both fasting and post-prandial serum insulin concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol focuses on the hypothesis that a deficiency in a putative inositolphosphoglycan
      (IPG) mediator of insulin action, namely a D-chiro-inositol-containing IPG (DCI-IPG),
      contributes to the insulin resistance of some women with PCOS. Our interest in this area
      stems directly from our previous studies, which demonstrated that administration of the
      precursor, D-chiro-inositol (DCI), to both obese and lean women with PCOS improved glucose
      intolerance while reducing circulating insulin, and simultaneously improved ovulatory
      function and decreased serum androgens. These findings were recently confirmed in a
      large-scale study by an independent group. The findings of these three studies suggested that
      administration of DCI improved insulin sensitivity in PCOS, which then resulted in an
      improved hormonal and metabolic milieu.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC DCI-IPG (%/Min)</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in the Area Under the Curve DCI-IPG measurements in blood samples taken at 15 minute intervals during the 2 hour OGTT before treatment with pioglitazone or placebo. Values reported as a percentage of bioactivity measured at time 0. Negative values indicate a decrease relative to the time 0 measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC DCI-IPG (%/Min)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in the Area Under the Curve DCI-IPG measurements in blood samples taken at 15 minute intervals during the 2 hour OGTT following 6 months of treatment with pioglitazone or placebo. Values reported as a percentage of bioactivity measured at time 0. Negative values indicate a decrease relative to the time 0 measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Serum Insulin</measure>
    <time_frame>baseline</time_frame>
    <description>Fasting serum insulin (uIU.min/ml) measured at 0, 60 and 120 minutes of a 2 hour OGTT before treatment with either pioglitazone or placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Serum Insulin (uIU/ml)</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting serum insulin (uIU.min/ml) measured at 0, 60 and 120 minutes of a 2 hour OGTT following 6 months treatment with either pioglitazone or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Matsuda Index</measure>
    <time_frame>Baseline</time_frame>
    <description>Whole body insulin sensitivity as determined by the Matsuda Index as calculated using the following formula:
10,000 divided by the square root of (FPI* FPG) * (xGPC* xIPC) Where FPI is fasting plasma insulin expressed as uU/ml, FPG is fasting plasma glucose expressed as mg/dL, xGPC is mean plasma glucose concentration after the load and xIPC is the mean insulin concentration after the load.
Values calculated on samples taken at 0, 30, 60, 90 and 120 minutes of a 2 hour OGTT. Values typically range from 0 to 12 units with higher scores indicating better insulin sensitivity. A value of 2.5 or less is indicative of insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Index</measure>
    <time_frame>6 months</time_frame>
    <description>Whole body insulin sensitivity as determined by the Matsuda Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>1/Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone in pill form at 45mg twice per day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2/Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>pioglitazone 45 mg</description>
    <arm_group_label>1/Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo daily</description>
    <arm_group_label>2/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Obese (Body Mass Index or BMI greater than or equal to 30 kg/m2) women with PCOS
             between 18-40 years of age:

               -  oligomenorrhea (less than 8 menstrual periods annually)

               -  biochemical hyperandrogenemia (elevated total or free testosterone)

               -  normal thyroid function tests and serum prolactin; AND

               -  exclusion of 21a-hydroxylase deficiency by a fasting 17a-hydroxyprogesterone less
                  than 200 ng/dl.51,

          2. acceptable health on the basis of interview, medical history, physical examination,
             and laboratory tests (Complete Blood Chemistry or CBC, Comprehensive Metabolic Panel
             denoted SMA20, urinalysis, negative pregnancy test).

          3. Signed, witnessed informed consent.

          4. Ability to comply with study requirements.

        Exclusion Criteria:

          1. Diabetes mellitus by fasting glucose or oral glucose tolerance test (OGTT), or
             clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric,
             infectious, neoplastic and malignant disease (other than non-melanoma skin cancer).

          2. Current use of oral contraceptives.

          3. Documented or suspected recent (within one year) history of drug abuse or alcoholism.

          4. Ingestion of any investigational drug within two months prior to study onset.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. Nestler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University General Clinical Research Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinical Caracas</name>
      <address>
        <city>Caracas</city>
        <zip>1071</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <results_reference>
    <citation>Gupta A, Jakubowicz D, Nestler JE. Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome. Metab Syndr Relat Disord. 2016 Oct;14(8):391-396. Epub 2016 Mar 30.</citation>
    <PMID>27028341</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <results_first_submitted>February 19, 2016</results_first_submitted>
  <results_first_submitted_qc>May 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2016</results_first_posted>
  <disposition_first_submitted>August 1, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 1, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 6, 2014</disposition_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Inositol phosphate glycan</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>individual data kept confidential, secured and not shared beyond authorized study staff</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1/Pioglitazaone Treated</title>
          <description>Pioglitazone treated subjects
pioglitazone: pioglitazone 45 mg</description>
        </group>
        <group group_id="P2">
          <title>2/Placebo</title>
          <description>Placebo control to arm 1
Placebo: placebo daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 32 obese (body mass index, BMI, greater than or equal to 30 kg/m2 PCOS women, between 18-40 years old, were studied during the equivalent of the follicular phase of the menstrual cycle, as documented by a serum progesterone of less than or equal to 2 ng/ml.</population>
      <group_list>
        <group group_id="B1">
          <title>1/Pioglitazaone Treated</title>
          <description>Pioglitazone treated subjects
pioglitazone: pioglitazone 45 mg</description>
        </group>
        <group group_id="B2">
          <title>2/Placebo</title>
          <description>Placebo control to arm 1
Placebo: placebo daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Females</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Venezuela</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC DCI-IPG (%/Min)</title>
        <description>Change in the Area Under the Curve DCI-IPG measurements in blood samples taken at 15 minute intervals during the 2 hour OGTT before treatment with pioglitazone or placebo. Values reported as a percentage of bioactivity measured at time 0. Negative values indicate a decrease relative to the time 0 measurement.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Pioglitazaone Treated</title>
            <description>Pioglitazone
pioglitazone: pioglitazone 45 mg</description>
          </group>
          <group group_id="O2">
            <title>2/Placebo</title>
            <description>control to arm 1
Placebo: placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>AUC DCI-IPG (%/Min)</title>
          <description>Change in the Area Under the Curve DCI-IPG measurements in blood samples taken at 15 minute intervals during the 2 hour OGTT before treatment with pioglitazone or placebo. Values reported as a percentage of bioactivity measured at time 0. Negative values indicate a decrease relative to the time 0 measurement.</description>
          <units>% bioactivity at time 0 of OGTT</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13162.06" spread="1240.6"/>
                    <measurement group_id="O2" value="14054.17" spread="1373.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Index</title>
        <description>Whole body insulin sensitivity as determined by the Matsuda Index as calculated using the following formula:
10,000 divided by the square root of (FPI* FPG) * (xGPC* xIPC) Where FPI is fasting plasma insulin expressed as uU/ml, FPG is fasting plasma glucose expressed as mg/dL, xGPC is mean plasma glucose concentration after the load and xIPC is the mean insulin concentration after the load.
Values calculated on samples taken at 0, 30, 60, 90 and 120 minutes of a 2 hour OGTT. Values typically range from 0 to 12 units with higher scores indicating better insulin sensitivity. A value of 2.5 or less is indicative of insulin resistance.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Pioglitazaone Treated</title>
            <description>Pioglitazone
pioglitazone: pioglitazone 45 mg</description>
          </group>
          <group group_id="O2">
            <title>2/Placebo</title>
            <description>control to arm 1
Placebo: placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Index</title>
          <description>Whole body insulin sensitivity as determined by the Matsuda Index as calculated using the following formula:
10,000 divided by the square root of (FPI* FPG) * (xGPC* xIPC) Where FPI is fasting plasma insulin expressed as uU/ml, FPG is fasting plasma glucose expressed as mg/dL, xGPC is mean plasma glucose concentration after the load and xIPC is the mean insulin concentration after the load.
Values calculated on samples taken at 0, 30, 60, 90 and 120 minutes of a 2 hour OGTT. Values typically range from 0 to 12 units with higher scores indicating better insulin sensitivity. A value of 2.5 or less is indicative of insulin resistance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="0.18"/>
                    <measurement group_id="O2" value="3.05" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC DCI-IPG (%/Min)</title>
        <description>Change in the Area Under the Curve DCI-IPG measurements in blood samples taken at 15 minute intervals during the 2 hour OGTT following 6 months of treatment with pioglitazone or placebo. Values reported as a percentage of bioactivity measured at time 0. Negative values indicate a decrease relative to the time 0 measurement.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Pioglitazaone Treated</title>
            <description>Pioglitazone
pioglitazone: pioglitazone 45 mg</description>
          </group>
          <group group_id="O2">
            <title>2/Placebo</title>
            <description>control to arm 1
Placebo: placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>AUC DCI-IPG (%/Min)</title>
          <description>Change in the Area Under the Curve DCI-IPG measurements in blood samples taken at 15 minute intervals during the 2 hour OGTT following 6 months of treatment with pioglitazone or placebo. Values reported as a percentage of bioactivity measured at time 0. Negative values indicate a decrease relative to the time 0 measurement.</description>
          <units>% bioactivity at time 0 of OGTT</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-412.22" spread="1295.7"/>
                    <measurement group_id="O2" value="-699.45" spread="1890.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Serum Insulin</title>
        <description>Fasting serum insulin (uIU.min/ml) measured at 0, 60 and 120 minutes of a 2 hour OGTT before treatment with either pioglitazone or placebo</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Pioglitazaone Treated</title>
            <description>Pioglitazone
pioglitazone: pioglitazone 45 mg</description>
          </group>
          <group group_id="O2">
            <title>2/Placebo</title>
            <description>control to arm 1
Placebo: placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Serum Insulin</title>
          <description>Fasting serum insulin (uIU.min/ml) measured at 0, 60 and 120 minutes of a 2 hour OGTT before treatment with either pioglitazone or placebo</description>
          <units>uIU.min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.04" spread="1.23"/>
                    <measurement group_id="O2" value="15.91" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Serum Insulin (uIU/ml)</title>
        <description>Fasting serum insulin (uIU.min/ml) measured at 0, 60 and 120 minutes of a 2 hour OGTT following 6 months treatment with either pioglitazone or placebo</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Pioglitazaone Treated</title>
            <description>Pioglitazone treated subjects
pioglitazone: pioglitazone 45 mg</description>
          </group>
          <group group_id="O2">
            <title>2/Placebo</title>
            <description>Placebo control to arm 1
Placebo: placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Serum Insulin (uIU/ml)</title>
          <description>Fasting serum insulin (uIU.min/ml) measured at 0, 60 and 120 minutes of a 2 hour OGTT following 6 months treatment with either pioglitazone or placebo</description>
          <units>uIU.min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.69" spread="1.23"/>
                    <measurement group_id="O2" value="-0.24" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Index</title>
        <description>Whole body insulin sensitivity as determined by the Matsuda Index</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Pioglitazaone Treated</title>
            <description>Pioglitazone
pioglitazone: pioglitazone 45 mg</description>
          </group>
          <group group_id="O2">
            <title>2/Placebo</title>
            <description>control to arm 1
Placebo: placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Index</title>
          <description>Whole body insulin sensitivity as determined by the Matsuda Index</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" spread="0.36"/>
                    <measurement group_id="O2" value="0.29" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1/Pioglitazone</title>
          <description>Pioglitazone in pill form at 45mg twice per day for 6 months
pioglitazone: pioglitazone 45 mg</description>
        </group>
        <group group_id="E2">
          <title>2/Placebo</title>
          <description>Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months
Placebo: placebo daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>weight gain due to edema</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Nestler</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>(804) 828-3389</phone>
      <email>john.nestler@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

